Directional local field potentials

Citation for published version:
Tinkhauser, G, Pogosyan, A, Debove, I, Nowacki, A, Shah, SA, Seidel, K, Tan, H, Brittain, J-S, Petermann, K, di Blase, L, Oertel, M, Pollo, C, Brown, P & Schuepbach, M 2018, 'Directional local field potentials: A tool to optimize deep brain stimulation', Movement Disorders, vol. 33, no. 1, pp. 159-164. https://doi.org/10.1002/mds.27215

Digital Object Identifier (DOI):
10.1002/mds.27215

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Movement Disorders

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
3. Anonymous. *Population estimates program*. Washington, DC: U.S. Census Bureau, 2017.

4. Colby SL, Ortmann JM. *Projections of the size and composition of the U.S. population: 2014-2060*. Washington, DC: U.S. Census Bureau, 2015.

5. Kalia LV, Lang AE. Parkinson’s disease. Lancet 2015;386(9996): 896-912.

6. Grandinetti A, Morens DM, Reed D, MacEachern D. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson’s disease. Am J Epidemiol 1994;139(12):1129-1138.

7. Pagani-Hill A. Risk factors for parkinson’s disease: the leisure world cohort study. Neuroepidemiology 2001;20(2):118-124.

8. Heran MA, Zhang SM, Rueda-deCastro AM, Collditz GA, Speizer FE, Ascherio A. Cigarette smoking and the incidence of Parkinson’s disease in two prospective studies. Ann Neurol 2001;50(6):780-786.

9. Heran MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol 2002;52(3):276-284.

10. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68(5):384-386.

11. Warren GW, Alberg AJ, Kraft AS, Cummings KM. The 2014 Surgeon General’s report: “The health consequences of smoking—50 years of progress”: a paradigm shift in cancer care. Cancer 2014;120(13):1914-1916.

12. Holford TR, Levy DT, McKay LA, et al. Patterns of birth cohort-specific smoking histories, 1963-2009. Am J Prev Med 2014;46(2):e31-e37.

13. Marek K, Jennings D, Seibyl J. Dopamine agonists and Parkinson’s disease progression: what can we learn from neuroimaging studies. Ann Neurol 2000;53(suppl 3):S160-S166.

14. Marek K, Jennings D. Can we image premotor Parkinson disease? Neurology 2009;72(7 suppl):S21-S26.

15. Chen H, Huang X, Guo X, et al. Smoking duration, intensity, and risk of Parkinson disease. Neurology 2010;74(11):878-884.

16. Davies HT, Crombie IK, Tavakoli M. When can odds ratios mislead? BMJ 1998;316(7136):989-991.

17. Thacker EL, O’Reilly EJ, Weiskopf MG, et al. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology 2007;68(10):764-768.

18. Bodenheimer T, Chen E, Bennett HD. Confronting the growing burden of chronic disease: can the U.S. health care workforce do the job? Health Aff (Project Hope) 2009;28(1):64-74.

19. Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson’s disease in the United States. Mov Disord 2013;28(3):311-318.

20. Noyes K, Liu H, Li Y, Holloway R, Dick AW. Economic burden associated with Parkinson’s disease on elderly Medicare beneficiaries. Mov Disord 2006;21(3):362-372.

21. Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G. Burden of illness in Parkinson’s disease. Mov Disord 2005;20(11):1449-1454.

22. O’Brien J, Ward A, Michels S, Tzvetkova S. Economic burden associated with Parkinson disease. Drug Benefit Trends 2009;21(6):179.

23. Beck JC, Alcalay R, Bower J, et al. Improving estimates of Parkinson’s disease prevalence and incidence in the USA [abstract]. Mov Disord 2014;29(suppl. 1):E1475.

24. Schoenberg BS, Anderson DW, Haerer AF. Prevalence of Parkinson’s disease in the biracial population of Copiah County, Mississippi. Neurology 1985;35(6):841-845.

25. Strickland D, Bertoni JM. Parkinson’s prevalence estimated by a state registry. Mov Disord 2004;19(3):318-323.

26. Morens DM, Davis JW, Grandinetti A, Ross GW, Popper JS, White LR. Epidemiologic observations on Parkinson’s disease: incidence and mortality in a prospective study of middle-aged men. Neurology 1996;46(4):1044-1050.

27. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999;52(6):1214-1220.

28. Mayeux R, Marder K, Cote LJ, et al. The frequency of idiopathic Parkinson’s disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am J Epidemiol 1995;142(8):820-827.

29. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003;157(11):1015-1022.

30. Safarpour D, Thibault DP, DeSanto CL, et al. Nursing home and end-of-life care in Parkinson disease. Neurology 2015;85(5):413-419.

31. Morozova N, O’Reilly EJ, Ascherio A. Variations in gender ratios support the connection between smoking and Parkinson’s disease. Mov Disord 2008;23(10):1414-1419.

32. Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA. Time trends in the incidence of Parkinson disease. JAMA Neurol 2016;73(8):981-989.

33. Office of Disease Prevention and Health Promotion. Healthy People 2020. Washington, DC: Office of Disease Prevention and Health Promotion. https://www.healthypeople.gov/2020/How-to-Use-DATA2020. Accessed 23 May 2017.

34. Ritz B, Lee PC, Lassen CF, Arah OA. Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease. Neurology 2014;83(16):1396-1402.

---

**Directions Local Field Potentials: A Tool to Optimize Deep Brain Stimulation**

Gerd Tinkhauser, MD, PhD,1,2,3* Alek Pogosyan, PhD,1,2

Ines Debove, MD,3 Andreas Nowacki, MD,4

Syed Ahmar Shah, PhD,1,2 Kathleen Seidel, MD,4

Huling Tan, PhD,1,2 John-Stuart Brittain, PhD,1,2

Katrin Petermann, Ing,3 Lazzaro di Biase, MD, PhD,1,2,5

Markus Oertel, MD,4,6 Claudio Pollo, MD,4

Peter Brown, MA, MBBS, MD,1,2 and Michael Schuepbach, MD3

1MRC Brain Network Dynamics Unit at the University of Oxford, Oxford, United Kingdom 2Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom 3West Wing, Level 6, John Radcliffe Hospital, OXG 0DX, United Kingdom; or Department of Neurology, Bern University Hospital, Freiburgstrasse, 3010 Bern, Switzerland; E-mail: gerd.tinkhauser@ndcn.ox.ac.uk

*Correspondence to: Dr. Gerd Tinkhauser, MRC Brain Network Dynamics Unit and Nuffield Department of Clinical Neurosciences, University of Oxford, West Wing, Level 6, John Radcliffe Hospital, OXG 0DX, United Kingdom; or Department of Neurology, Bern University Hospital, Freiburgstrasse, 3010 Bern, Switzerland; E-mail: gerd.tinkhauser@ndcn.ox.ac.uk

P.B. and M.S. are joint senior authors.

Funding agencies: G.T. is funded by the Rosetrees Trust, the National Institute of Health Research Oxford Biomedical Research Center, and the European Academy of Neurology (EAN). P.B., A.P., and H.T. are funded by the Medical Research Council (MC_UU_12024/1), and S.A.S. by the Medical Research Council (MR/N003446/1), and S.A.S. by the Rosetrees Trust.

Relevant conflicts of interest/financial disclosures: G.T. received financial support for congress participation from Boston Scientific. I.D. received financial support from Boston Scientific.

Full financial disclosures and author roles may be found in the online version of this article.

Received: 28 June 2017; Revised: 21 August 2017; Accepted: 3 October 2017

Published online 18 November 2017 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.27215

---
ABSTRACT

Background: Although recently introduced directional DBS leads provide control of the stimulation field, programming is time-consuming.

Objectives: Here, we validate local field potentials recorded from directional contacts as a predictor of the most efficient contacts for stimulation in patients with PD.

Methods: Intraoperative local field potentials were recorded from directional contacts in the STN of 12 patients and beta activity compared with the results of the clinical contact review performed after 4 to 7 months.

Results: Normalized beta activity was positively correlated with the contact’s clinical efficacy. The two contacts with the highest beta activity included the most efficient stimulation contact in up to 92% and with the widest therapeutic window in 74% of cases.

Conclusion: Local field potentials predict the most efficient stimulation contacts and may provide a useful tool to expedite the selection of the optimal contact for directional DBS.

Key Words: Parkinson’s disease; deep brain stimulation; directional leads; local field potentials; DBS programming

A major advance in DBS technology was the introduction of directional DBS leads with segmented contacts and multiple source current steering.\(^1,2\) The middle two levels of conventional ring-contact DBS electrodes are replaced with three segmented (noncircular) contacts (Fig. 1A), which allow steering of the stimulation field. Two intraoperative studies,\(^1,3\) a postoperative clinical trial and a case report,\(^4,5\) have reported an increased therapeutic window and efficacy of directional compared to spherical stimulation.

These advantages are offset by the complexity of programming directional DBS. The monopolar contact review is the crucial initial step and gold standard for the management of DBS patients\(^6,7\) and requires a highly trained person.\(^8\) The use of directional DBS leads implies testing of a total of 16 stimulation contacts (8/hemisphere), with 12 (6/hemisphere) of them being segmented (Fig. 1A) and requires much more time. Thus, tools that can expedite programming and optimize the use of directional electrodes are strongly needed.\(^9\)

Local field potential (LFP) activity in the beta band (13–35 Hz) has previously been shown to be related to motor symptoms in Parkinson’s disease (PD) and to predominantly arise in the motor portion of the STN.\(^10,11\) Importantly, it has also been demonstrated that the ring contact closest to the beta source is clinically more efficient compared to other contacts.\(^11,13,15\)

Here, we test the hypothesis that delivery of stimulation in the direction of the highest beta-band activity in the STN provides the best stimulation effect and that the LFP may therefore serve as a tool to assist DBS programming.

Patients and Methods

Twelve PD patients undergoing STN-DBS surgery were implanted with directional leads (Boston Scientific, Marlborough, MA; Supplementary Table 1). LFPs were recorded during surgery from the directional contacts after each lead was placed in its final position (Fig. 1B). Normalized beta activity was derived from each directional contact by normalization of the individual beta peak activity by the whole beta band (13–35 Hz). In cases where no beta peak was present, the low beta band (13–20 Hz) was normalized. Monopolar contact review took place 4 to 7 months postsurgery. Clinical efficacy (% rigidity improvement/stimulation current) and therapeutic window (TW) were calculated for each directional contact and compared with the corresponding normalized beta activity. Detailed methods are included in the Supplementary Material.

Results

Relationship Between Beta Activity and Response to stimulation

In 15 of 19 hemispheres tested, we found a positive relationship (t\(_{18} = 4.65; P < 0.001,\) one-sample t test) between normalized beta activity and clinical efficacy (ranked values: Fig. 1C; absolute nonranked values: Supplementary Fig. 3). Thus, the higher the relative beta activity recorded from a specific directional contact, the better its clinical efficacy. In all cases, the contact with highest beta was consistently one of those with higher clinical efficacy, and in 12 of 19 cases (63%), it corresponded to the contact with the highest clinical efficacy. In 7 of 19 cases (36%; hemispheres 13–19), we did not find a clear beta peak, but despite this, the relationship was similar to those with a clear peak in the beta band. There was also no difference in the predictive value of the level and orientation of the beta peak between those hemispheres with a beta peak up to 20 Hz (=2, 3, 5, 6, 7, 10, and 11) and those hemispheres with a beta peak above 20 Hz (hemispheres 1, 4, 8, 9, and 12). The ring level
containing the contact with the highest beta activity was localized in the dorsal STN (ventral STN = 0; middle STN = 4; dorsal STN = 15).

**Predictive Value of Beta Activity for the Most Efficient Stimulation Contact**

In Figure 2A, we tested the predictive value of contacts ranked by relative beta power for clinical efficacy. This shows that the stimulation contact with the highest beta activity was able to predict the stimulation contact with the highest clinical efficacy in 63% of cases. More strikingly, when including the contact with the second-highest beta activity, the prediction rose to 84%, and up to 92% if only hemispheres with a clear beta peak (n = 12) were considered. In contrast, conventional clinical testing had only a 17% likelihood of identifying the most efficient contact if only one contact was assessed, and a 34% likelihood if two contacts were assessed. Figure 2B shows that the mean clinical efficacy of the two contacts with the highest beta activity was significantly higher (31.3 ± 3.2%/mA [milliamperes]) compared to the mean clinical efficacy (26.1 ± 2.7%/mA) of the remaining contacts of the same electrode (t_{18} = 3.75; P = 0.0015, paired t test).

**Relationship Between Clinical Efficacy and Therapeutic Window**

Another important clinical parameter is the therapeutic window, which also includes the side-effect threshold. Figure 2C shows that the LFP-based strategy identified the contact with the widest therapeutic window in 42% of cases if only the contact with the highest beta activity was considered, and in 74% if the two highest beta contacts were considered. No relevant difference in the predictive value was found when hemispheres with a clear beta peak were exclusively considered. Additionally, Figure 2D shows that the mean therapeutic window of the two contacts with the highest beta activity was significantly higher (1.45 ± 0.27 mA) compared to the mean TW (0.96 ± 0.17 mA) of the remaining contacts of the same electrode (t_{18} = 3.11; P = 0.006, paired t test).

**Discussion**

In this study, we demonstrate, in a sizeable patient cohort, that the two segmented contacts of the directional DBS electrode with maximal STN beta activity are highly likely to include the contact that turns out to have the best efficacy with a wide therapeutic window. Clinical testing was performed at least 4 months after lead implantation, when the majority of any stun effect has lapsed\(^16\) and the clinical relevance of contact screening therefore heightened. Thus, the LFP can serve as a predictive and supportive tool for multicontact lead programming. This is in line with previous studies showing similar results for the ring contact electrode\(^11,13-15\) as well as with an intraoperative trial\(^17\) and a single, early postoperative case report with directional stimulation.\(^18\)

Why should beta power in the LFP predict the clinical efficacy of stimulation fields of different orientation? It has been shown that the dorsal part of STN is the most effective site for STN stimulation in PD\(^19,20\) and that this is also the focus of beta activity.\(^11-13\) Yet, the LFP cannot afford direct information about the contact specific therapeutic window, because side effect threshold depends on the vicinity of the stimulation field to neighboring structures. On the other hand, as current directed to the dorsal STN is less likely to spread to these neighboring areas, the prediction of the contact with the lowest threshold for clinical effect may also explain the predictive value for the contact with the widest therapeutic window.

**LFP-Based Programming**

If we assume that it takes around 20 minutes to assess stimulation at each contact, then monopolar contact review of segmented leads will take around 4 hours (12 segmented contacts). This would be fatigue inducing for both clinician and patient, leading to variability in assessments. If only those two segmented contacts that have the highest beta activity are screened on each side, then there is approximately a 90% probability of selecting the contacts that have the lowest effect threshold. This would only take 80 minutes, reducing assessment time by approximately two thirds. Moreover, as discussed...

---

**FIG. 1.** Directional LFPs and relationship between ranked beta activity and clinical efficacy. (A) illustrates the directional DBS lead (Boston Scientific, Marlborough, MA). Contacts are distributed along four levels. On levels two and three, there are 3 segmented contacts (level two: contacts 2/3/4; level three: contacts 5/6/7). (B) shows an example time frequency spectrum from an intraoperative LFP recording (duration, 100 seconds) from the six directional contacts (2/3/4, 5/6/7) with the patient awake and at rest. The dashed white line marks the beta frequency band (13-35 Hz). It shows that LFP beta activity is not equally distributed across directional contacts. Contact 5 shows the highest beta activity, followed by contact 2, with both contacts 5 and 2 oriented in the same direction. Data from the right hemisphere in subject 3 (for raw data, amplitude-frequency spectrum, and imaging from the same subject and hemisphere, see Supplementary Fig. 1). (C) illustrates the relationships between normalized beta activity and clinical efficacy across the six directional contacts in each hemisphere (H = hemisphere; n = 19). The normalized beta amplitude is shown on the x-axis, the clinical efficacy on the y-axis, and Spearman correlation coefficients are shown on the top of each panel. The best electrophysiological contact (contact with highest normalized beta activity) is highlighted in black. The red linear regression fit is shown only for illustration purposes. In 15 hemispheres, a positive relationship between clinical efficacy and normalized beta activity was found (r_{xy} = 4.65; P < 0.001, one-sample t test). In 12 of 19 hemispheres, the contact with the highest beta activity matched the clinically most effective stimulation contact. Furthermore, in all hemispheres, the contact with the highest beta activity was localized in the upper-right quadrant, where the clinically more efficient contacts are localized. Clinical efficacy and normalized beta activity are illustrated as ranked values; Supplementary Figure 3 shows the same figure with nonranked values. [Color figure can be viewed at wileyonlinelibrary.com]
above, the two segmented contacts with the highest beta activity are also more likely to have a wider therapeutic window. Hence, this method potentially offers a physiologically based, time-saving approach to the programming of directional electrodes.

**Limitations**

In this investigation, we only studied those sides with at least two points of upper-limb rigidity and more than a minimum range of responses to stimulation across contacts. We also limited the electrophysiological-clinical comparison to the clinical data acquired during the monopolar review session, where rigidity was the only systematically assessed item. However, rigidity is also the most sensitive clinical sign to DBS.6 These inclusion criteria were chosen to optimize the clinical comparison across contacts, and to avoid ceiling and floor effects. The value of beta activity and of other LFP features in predicting the best contact for tremor suppression needs further evaluation.

In addition, we assumed that the monopolar review in and of itself is predictive of chronic stimulation settings.6,19 Moreover, manual clinical contact testing,
although the current “gold standard” for determining the best stimulation contacts, is a subjective method with some degree of inter-rater variability. Any noise in the gold-standard estimation will only have served to degrade the apparent predictive value of the LFP.

Intraoperative time constraints meant that LFPs could only be recorded for around 2 minutes (with interindividual variability), and longer recordings might have been more representative. Importantly, we also assumed that lead position and orientation did not change after LFP recording. Furthermore, our data may have been contaminated by stun effects, which can be detected as the STN is traversed and lead to diminished beta power.10

Future Directions and Conclusion

Tools that can assist DBS programming by the clinician or even run fully automatically are desirable in this era of directional, multicontact leads. This could streamline the postoperative management of patients, and free up clinical resources to contend with the increasing numbers of such patients dictated by growing experience with this therapy and by the move to offer DBS earlier during the disease course.21 Nevertheless, the clinical advantage, or lack thereof, of chronic directional DBS still needs to be definitively demonstrated.

The method presented is of potential predictive value with respect to subsequent programming, regardless of whether microelectrode recordings are used or not in targeting the STN. In time, optimal contact prediction might be based on a variety of features. The electrophysiological approach taken here might be supplemented by radiological-anatomical strategies that could provide more-accurate information about surrounding structures. However, presently, these are challenging to implement, given that target structures are small and image resolution is limited, so that the error rate in lead localization is not negligible.22

In conclusion, the present study suggests that the amplitude of subthalamic beta LFP activity is predictive of the most efficient stimulation contact and can form the basis for a rapid programming tool useful for multicontact directional DBS leads. ●

References

1. Pollo C, Kaelin-Lang A, Oertel MF, et al. Directional deep brain stimulation: an intraoperative double-blind pilot study. Brain 2014;137:2015-2026.
2. Timmermann L, Jain R, Chen L, et al. Multiple-source current steering in subthalamic nucleus deep brain stimulation for Parkinson’s disease (the VANTAGE study): a non-randomised, prospective, multicentre, open-label study. Lancet Neurol 2015;14:693-701.
3. Contarino MF, Bour LJ, Verhagen R, et al. Directional steering: a novel approach to deep brain stimulation. Neurology 2014;83:1163-1169.
4. Steigerwald F, Müller L, Johannes S, Matthies C, Volkmann J. Directional deep brain stimulation of the subthalamic nucleus: a pilot study using a novel neurostimulation device. Mov Disord 2016;31:1240-1243.
5. Reker P, Dembek TA, Becker J, et al. Directional deep brain stimulation: a case of avoiding dystonia with bipolar directional current steering. Parkinsonism Relat Disord 2016;31:156-158.
6. Volkmann J, Moro E, Pahwa R. Basic algorithms for the programming of deep brain stimulation in Parkinson’s disease. Mov Disord 2006;21:284-289.
7. Picillo M, Lozano AM, Kou N, et al. Programming deep brain stimulation for Parkinson’s disease: The Toronto Western Hospital Algorithms. Brain Stimul 2016;9:425-437.
8. Moro E, Poon YY, Lozano AM, et al. Subthalamic nucleus stimulation: improvements in outcome with reprogramming. Arch Neurol 2006;63:1266-1272.
9. Kühn AA, Volkmann J. Innovations in deep brain stimulation methodology. Mov Disord 2017;32:11-19.
10. Chen CC, Pogosyan A, Zrinzo LU, et al. Intra-operative recordings of local field potentials can help localize the subthalamic nucleus in Parkinson’s disease surgery. Exp Neurol 2006;198:214-221.
11. Zaidel A, Spivak A, Grieb B, Bergman H, Israel Z. Subthalamic span of beta oscillations predicts deep brain stimulation efficacy for patients with Parkinson’s disease. Brain 2010;133( Pt 7):2007-2021.
12. Hom A, Neumann WJ, Degen K, Schneider GH, Kühn AA. Toward an electrophysiological ‘sweet spot’ for deep brain stimulation in the subthalamic nucleus, Hum Brain Mapp 2017 Apr 8. doi: 10.1002/hbm.23594. [Epub ahead of print]
13. Yoshida F, Martinez-Torres I, Pogosyan A, et al. Value of subthalamic nucleus local field potentials recordings in predicting stimulation parameters for deep brain stimulation in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2010;81:885-889.
14. Ince NF, Gupte A, Wichmann T, et al. Selection of optimal programming contacts based on local field potential recordings from subthalamic nucleus in patients with Parkinson’s disease. Neurosurgery. 2010;67:390-397.
15. Connolly AT, Kaemmerer WF, Dani S, et al. Guiding deep brain stimulation contact selection using local field potentials sensed by a chronically implanted device in Parkinson’s disease patients. In: International IEEE/EMBS Conference on Neural Engineering, NER (Vol. 2015-July, pp. 840-843). [7146754] IEEE Computer Society. doi: 10.1109/NER.2015.7146754.
16. Mestre TA, Lang AE, Okun MS. Factors influencing the outcome of deep brain stimulation: placebo, nocebo, lesebo, and lesion effects. Mov Disord 2016;31:290-298.
17. Bour LJ, Lourens MA, Verhagen R, de Bie RM, van den Munchkopf P, Schuurman PR, Contarino MF. Directional recording of subthalamic spectral power densities in Parkinson’s disease and the effect of steering deep brain stimulation. Brain Stimul 2015;8:1-12.
18. Fernández-García C, Foffani G, Dileone M, Catalán-Alonso MJ, González-Hidalgo M, García JA, Alonso-Frech F. Directional local field potential recordings for symptom-specific optimization of deep brain stimulation. Mov Disord 2017;32:626-628.
19. Herzog J, Fietzek U, Hamel W, et al. Most effective stimulation site in subthalamic deep brain stimulation for Parkinson’s disease. Mov Disord 2004;19:1050-1054.
20. Pollo C, Vingerhoets F, Pralong E, et al. Localization of electrodes in the subthalamic nucleus on magnetic resonance imaging. J Neurosurg 2007;106:36-44.
21. Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med 2013;368:610-622.
22. Nestor KA, Jones JD, Butson CR, et al. Coordinate-based lead location does not predict Parkinson’s disease deep brain stimulation outcome. PLoS One 2014;9:e93524.

Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher’s web-site.